Aragon Surgical is a technology company.
Aragon Surgical has raised $25.0M across 1 funding round.
Aragon Surgical has raised $25.0M in total across 1 funding round.
Aragon Surgical was a medical device company that developed innovative surgical instruments to reduce operative time and enhance patient safety, primarily targeting gynecologic, general, and laparoscopic surgeons.[1][3][4] Its key products included radiofrequency (RF) electrosurgical devices like the OS12 for open hysterectomy, L2 for laparoscopic surgery, and a general surgery tool, alongside the LapCap—a pneumoperitoneum creation assist device that safely elevates the abdominal wall for laparoscopic procedures.[1][2] The company served surgeons and hospitals by addressing inefficiencies in tissue cauterization, fusion, and cutting, ultimately streamlining operations and minimizing recovery times; it raised $33M from investors including Aesculap, Delphi Ventures, and ONSET Ventures before being acquired.[1]
Founded in 2005 in Palo Alto, California, Aragon Surgical emerged as a venture-backed, surgeon-driven company focused on commercializing devices that improve surgical performance.[1][3][5] While specific founders are not detailed in available records, the firm collaborated closely with surgeons to pinpoint pain points in operative procedures, leading to early investments from Delphi Ventures and ONSET Ventures.[3] Pivotal early developments included filing patents starting in 2006 for tissue cauterization apparatus and launching products like the LapCap, which introduced a novel suction-based method for safer laparoscopic access.[1][2] Headquartered at 1810 Embarcadero Road (with some records noting a Redwood City address), it grew to around 29 employees before reaching the acquired stage.[1][3][5]
Aragon Surgical rode the wave of minimally invasive surgery trends in the mid-2000s, capitalizing on growing demand for laparoscopic and endoscopic tools amid rising healthcare costs and emphasis on patient outcomes.[1][2] Its timing aligned with advancements in RF electrosurgery and single-incision techniques, addressing market needs for faster procedures amid competitors like Cambridge Endoscopic Devices and FloShield.[1] By reducing operative times and risks, it influenced the medtech ecosystem, contributing to safer pneumoperitoneum creation and tissue management—key enablers for broader adoption of less invasive surgeries in hospitals worldwide.[2][4]
Acquired after raising $33M, Aragon Surgical's technologies likely integrated into the acquirer's portfolio, amplifying its legacy in RF electrosurgery and laparoscopic aids.[1] Looking ahead, its innovations position it to shape ongoing trends in robotic-assisted and AI-enhanced minimally invasive surgery, where speed and precision remain critical amid aging populations and value-based care. As medtech consolidates, expect its IP to drive efficiencies in acquirer's products, sustaining impact on surgical standards and patient recovery. This underscores Aragon's role as a pioneer in tools that eliminate procedural inefficiencies, tying back to its mission of safer, swifter operations.
Aragon Surgical has raised $25.0M in total across 1 funding round.
Aragon Surgical's investors include GE Ventures.
Aragon Surgical has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series B in January 2008.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2008 | $25.0M Series B | GE Ventures |